<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03229850</url>
  </required_header>
  <id_info>
    <org_study_id>H17-01270</org_study_id>
    <nct_id>NCT03229850</nct_id>
  </id_info>
  <brief_title>Dynamics of Insulin Absorption in Subclinical Lipohypertrophy Using the Euglycemic Clamp Technique</brief_title>
  <official_title>Dynamics of Insulin Absorption in Subclinical Lipohypertrophy Using the Euglycemic Clamp Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Graydon Meneilly</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will use the euglycemic clamp technique to evaluate insulin absorption when
      insulin is administered subcutaneously in an area of subclinical lipohypertrophy vs an area
      of normal tissue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of insulin to manage diabetes can cause changes to the skin at sites where insulin is
      administered. These changes may be felt as lumps under the skin. Insulin injected into these
      areas may not work as well leading to needing increasing doses of insulin to control blood
      glucose levels. Hypoglycemia can occur when insulin is injected into normal areas. Previous
      studies have found that these lipohypertrophic areas can be seen on ultrasound before they
      can be felt. The Investigators will be using the euglycemic clamp techique to evaluate
      insulin absorption to see whether tissue with lumps that cannot be felt but are seen on
      ultrasound affect how insulin is absorbed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>During one euglycemic clamp study, insulin lispro will be injected subcutaneously into an area of subclinical lipohypertrophy of the abdomen identified by ultrasound, during the other insulin lispro will be injected to an area with no subclinical lipohypertrophy.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Levels</measure>
    <time_frame>2 months</time_frame>
    <description>The euglycemic clamp technique will be used. Insulin levels will be analyzed by Eliza assay</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Lipohypertrophy</condition>
  <arm_group>
    <arm_group_label>Subclinical Lipohypertrophy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Insulin lispro will be injected in the abdomen into an area of subclinical lipohypertrophy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Subclinical Lipohypertrophy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Insulin lispro will be injected in the abdomen into an area where there is no subclinical lipohypertrophy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin lispro</intervention_name>
    <description>Insulin lispro will be injected into the abdomen into an area of subclinical lipohypertrophy or an area with no subclinical lipohypertrophy</description>
    <arm_group_label>Subclinical Lipohypertrophy</arm_group_label>
    <arm_group_label>No Subclinical Lipohypertrophy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participated in Glycemic Variability study

          -  Type 2 Diabetes for at least 2 years

          -  Currently using insulin to manage diabetes

          -  Have used insulin to manage diabetes for at least 2 years

          -  Age 19 or older

          -  BMI &lt; 30 kg/m2

          -  Confirmed areas of subclinical lipohypertrophic adipose tissue lesions via ultrasound

        Exclusion Criteria:

          -  Taking other injectable medications (eg liraglutide/Victoza

          -  Taking systemic steroids (ie prednisone)

          -  Severe renal insufficiency (eGFR &lt; 30 ml/min/1.73 m2

          -  Hypoglycemic unawareness

          -  Current pregnancy

          -  Not fluent in speaking and writing English (unless accompanied by a translator)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graydon Meneilly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boris Feldman</last_name>
    <phone>604-875-5115</phone>
    <email>boris.feldman@vch.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of British Columbia - Gerontology Research Lab</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Boris Feldman</last_name>
      <phone>604-875-5115</phone>
      <email>boris.feldman@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Graydon S Meneilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jordanna Kapeluto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Fujikura J, Fujimoto M, Yasue S, Noguchi M, Masuzaki H, Hosoda K, Tachibana T, Sugihara H, Nakao K. Insulin-induced lipohypertrophy: report of a case with histopathology. Endocr J. 2005 Oct;52(5):623-8.</citation>
    <PMID>16284443</PMID>
  </reference>
  <reference>
    <citation>Raile K, Noelle V, Landgraf R, Schwarz HP. Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes. 2001;109(8):393-6.</citation>
    <PMID>11748486</PMID>
  </reference>
  <reference>
    <citation>Schiazza L, Occella C, Bleidl D, Rampini E. Insulin lipohypertrophy. J Am Acad Dermatol. 1990 Jan;22(1):148-9.</citation>
    <PMID>2076114</PMID>
  </reference>
  <reference>
    <citation>Vardar B, Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract. 2007 Aug;77(2):231-6. Epub 2007 Feb 15.</citation>
    <PMID>17303282</PMID>
  </reference>
  <reference>
    <citation>Young RJ, Hannan WJ, Frier BM, Steel JM, Duncan LJ. Diabetic lipohypertrophy delays insulin absorption. Diabetes Care. 1984 Sep-Oct;7(5):479-80.</citation>
    <PMID>6389062</PMID>
  </reference>
  <reference>
    <citation>Chowdhury TA, Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. BMJ. 2003 Aug 16;327(7411):383-4.</citation>
    <PMID>12919996</PMID>
  </reference>
  <reference>
    <citation>Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes. 1996;104(2):106-10.</citation>
    <PMID>8740933</PMID>
  </reference>
  <reference>
    <citation>Blanco M, Hern√°ndez MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013 Oct;39(5):445-53. doi: 10.1016/j.diabet.2013.05.006. Epub 2013 Jul 22.</citation>
    <PMID>23886784</PMID>
  </reference>
  <reference>
    <citation>Thow JC, Johnson AB, Marsden S, Taylor R, Home PD. Morphology of palpably abnormal injection sites and effects on absorption of isophane(NPH) insulin. Diabet Med. 1990 Nov;7(9):795-9.</citation>
    <PMID>2148131</PMID>
  </reference>
  <reference>
    <citation>Overland J, Molyneaux L, Tewari S, Fatouros R, Melville P, Foote D, Wu T, Yue DK. Lipohypertrophy: does it matter in daily life? A study using a continuous glucose monitoring system. Diabetes Obes Metab. 2009 May;11(5):460-3. doi: 10.1111/j.1463-1326.2008.00972.x. Epub 2009 Feb 19.</citation>
    <PMID>19236441</PMID>
  </reference>
  <reference>
    <citation>Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care. 1998 Nov;21(11):1910-4.</citation>
    <PMID>9802742</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>July 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2017</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Graydon Meneilly</investigator_full_name>
    <investigator_title>Professor, UBC Department of Medicine</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Insulin</keyword>
  <keyword>Lipohypertrophy</keyword>
  <keyword>Euglycemic Clamp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

